Antihistamine drugs do not meaningfully control eczema symptoms and may carry potential risks, according to new research reported by The Independent.
Canadian researchers analysed 47 clinical trials involving more than 6,200 children and adults with moderate or severe atopic dermatitis. Compared with placebo, antihistamines produced only a clinically insignificant reduction in eczema severity and itching.
The research also indicated that the drugs may not improve sleep quality or prevent eczema flare-ups. Currently, antihistamines can be used during allergy-related flare-ups, with sedating forms prescribed short-term to ease sleep when itching is severe.
First-generation antihistamines, which commonly cause drowsiness, were found to carry additional concerns. The researchers said those drugs could worsen cognitive impairment, affecting attention, memory and thinking, and could also lead patients to discontinue treatment because of side effects.
The researchers concluded that their findings do not support the routine use of antihistamines for atopic dermatitis. They said the work lays the groundwork for evidence-based changes to clinical practice and should prompt updated guidelines with a focus on effectiveness, safety and a patient-centred approach.
